News of Note—Sanofi, Dynavax and more

newspaper
(Pixabay)

Here is some other vaccine news of note for the week:

> The FDA approved an expanded use for Sanofi's Tdap vaccine Adacel to allow for repeat vaccinations. Release

> Dynavax predicts an "inflection point" in sales for its Heplisav-B vaccine and that the vaccine will be profitable by the end of 2019. Presentation

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

> The Coalition for Epidemic Preparedness Innovations (CEPI) tapped the University of Queensland in a deal worth up to $10.6 million to develop a “molecular clamp” vaccine platform, which enables rapid vaccine production against multiple viral pathogens. Release

> Univercells launched its low-cost vaccine production system, NevoLine, triggering a $4 million grant extension from the Bill & Melinda Gates Foundation to scale up the platform. Release

Read more on

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.